Global Secondary Hyperparathyroidism Treatment Market - 2023-2030

Overview

Global Secondary Hyperparathyroidism Treatment Market reached US$ 4.3 billion in 2022 and is expected to reach US$ 8.5 billion by 2030 growing with a CAGR of 9.2% during the forecast period 2023-2030. The trend such as the shift towards personalized medicine due to its advances in genetics and biomarker research enables in development of targeted therapies is expected to dominate the global secondary hyperparathyroidism treatment market.

The global secondary hyperparathyroidism treatment market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such emergence of new therapies such as calcimimetics.

Furthermore, the rising prevalence of chronic kidney disease, increasing aging population, decreasing calcium deficiency, increasing number of clinical trials are driving up the secondary hyperparathyroidism treatment market size. The growing research activities for treating disease using secondary hyperparathyroidism treatment approach and presence of establish biopharmaceutical and pharmaceutical companies are some of the factors in demand from North American regions. With significant competitors like OPKO HEALTH, INC., Amgen Inc., and others actively operating in the market.

Dynamics

The Increasing Number of Geriatric Population to Drive the Growth of the Secondary Hyperparathyroidism Treatment Market

The growing number of elderly population is expected to drive the demand for secondary hyperparathyroidism treatment market. This growth is due to elevated prevalence of chronic kidney disease resulting in subsequent secondary hyperparathyroidism (SHPT) growth. For instance, according to World Health Organization 2022 report, 1 out of 6 people in the world will be aged 60 years or over by 2030. At this point, the population aged 60 and up will climb from 1 billion in 2020 to 1.4 billion.

Moreover by 2050, the world's population of persons aged 60 and up will have doubled (2.1 billion). Between 2020 and 2050, the number of people aged 80 and more is expected to treble, reaching 426 Billion. Furthermore, vitamin D deficiency is commonly seen in geriatric patients that results in secondary hyperparathyroidism. As geriatric population increases the demand for effective treatments is likely to happen. Thus, owing to the above factors the market is expected to drive over the forecast period.

The Increasing Number of Vitamin D Deficiency will Drive the Secondary Hyperparathyroidism Treatment Market Growth

The secondary hyperparathyroidism treatment market is expected to drive owing to the lack of vitamin D. The condition is distinguished by rapid bone turnover, bone loss, mineralization defects, and hip and other fractures. Vitamin D deficiency is prevalent among the elderly, particularly in those who are housebound or have a medical condition.

For instance, according to the Cleveland Clinic Organization 2022 article, Vitamin D deficiency is a major global concern. Around 1 billion people worldwide are vitamin D deficient, whereas 50% are vitamin D insufficient. Vitamin D insufficiency affects approximately 35% of adults in the U.S. To reduce the risk of secondary hyperparathyroidism, vitamin D insufficiency should be avoided or addressed with vitamin D supplementation. Thus, owing to the above factors the market is expected to dominate the market over the forecast period.

The High Cost Associated with the Secondary Hyperparathyroidism Treatment Will Hamper the Growth of the Market

The high expense of medications used to treat secondary hyperparathyroidism (SHPT) may stop individuals from obtaining effective treatment, particularly those who live in regions with limited healthcare coverage or affordability.

For instance, sensipar (cinacalcet) is a well-known calcimimetic medication used to treat illnesses such as primary hyperparathyroidism, and secondary hyperparathyroidism. Sensipar's oral tablet at the 30 mg dosage costs about $859 for a 30-tablet supply. Therefore, this high cost associated with the drug may impede the widespread use of new medicines and thereby hampering the market growth.

Segment Analysis

The global secondary hyperparathyroidism treatment market is segmented based on drug class, route of administration, distribution channel and region.

Owing to the Better Effectiveness, the Vitamin D Analogs Segment Accounted for Approximately 49.5% of the Secondary Hyperparathyroidism Treatment Market Share

The vitamin D analogs segment is poised to dominate the secondary hyperparathyroidism treatment market due to its better clinical efficacy in managing the secondary hyperparathyroidism, broader clinical applications, and availability of formulations available in the market. Vitamin D analogs are a type of drug used to treat secondary hyperparathyroidism, a condition in which the parathyroid glands develop excessive amounts of parathyroid hormone (PTH) due to low calcium and vitamin D levels in the blood.

These analogs are intended to decrease PTH gene transcription and parathyroid hyperplasia while having lower calcemic activity, making them a safer alternative to calcitriol. Vitamin D analogs have been shown to improve patient survival in chronic kidney disease (CKD) and correct PTH levels in stage 3 and 4 CKD, potentially preventing renal bone damage and extending patient survival.

Furthermore, vitamin D analogs currently in use include calcifediol, paricalcitol, and doxercalciferol. Newer analogs with higher selectivity are also being developed. Overall, because of their effectiveness and safety in comparison to alternative treatments, vitamin D analogs are positioned to dominate the global secondary hyperparathyroidism market. Thus, due to better efficacy and effectiveness the segment is expected to dominate over the forecast period.

Geographical Penetration

North America Accounted for Approximately 39.1% of the Market Share in 2022, Owing to the Rising Prevalence of Chronic Kidney Disease

North America, particularly the U.S., dominates the global secondary hyperparathyroidism treatment market due to presence of huge number of key players settled in the region, growing prevalence of chronic kidney disease, and high research activities along with increasing clinical trial by major organization in the region. The high prevalence of CKD driving the demand for market in this region owing to the factors such as escalating aging population, sedentary lifestyle, a high prevalence of diabetes and hypertension.

For instance, according to Centers for Disease Control and Prevention 2022 report, approximately the prevalence of chronic kidney disease (CKD) in the U.S. is more than 1 in 7 adults-about 35.5 Billion people, or 14%. Furthermore, CKD is more common in people aging above 65 years and women are more prevalent in compae to men for CKD. Thus, owing to above factors the region is expected to grow over the forecast period.

Competitive Landscape

The major global players in the secondary hyperparathyroidism treatment market include: OPKO HEALTH, INC., Amgen Inc., Tairui Biotechnology Co., Ltd., sanofi SA, Validus Pharmaceuticals LLC, AbbVie Inc., ONO PHARMACEUTICAL CO., LTD, Kyowa Kirin Co., Ltd., Teva Pharmaceuticals USA, Inc., Pharmanovia, and among others.

COVID-19 Impact Analysis

COVID-19 may affect parathyroid gland functioning in two ways which are directly by invasion and indirectly via vitamin D insufficiency and secondary hyperparathyroidism. COVID-19 can be considered a direct cause of hypoparathyroidism. When combined with secondary hyperparathyroidism, vitamin D deficiency may have an adverse effect on the clinical outcome of COVID-19. COVID-19 has had an impact on the care of patients with hypoparathyroidism and hyperparathyroidism.

However, studies suggest that there is no direct evidence that having primary hyperparathyroidism makes the individual more prone to get COVID-19 than anyone else. As a result, the link between COVID-19 and secondary hyperparathyroidism is that COVID-19 might indirectly affect parathyroid gland function via vitamin D insufficiency and secondary hyperparathyroidism, which may have a negative effect on COVID-19's clinical outcome.

By Drug Class

• Vitamin D Analogs
• Calcimimetics
• Phosphate Binders
• Others

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On October 5, 2020, Dr. Reddy's Laboratories Ltd. and its subsidiaries announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets that has been approved by the U.S. Food and Drug Administration (USFDA).

DMI Opinion

The global secondary hyperparathyroidism treatment market is expected to increase due to rising personalized medicine trends fueled by genetic and biomarker advances. Market growth is fueled by factors such as the emergence of drugs such as calcimimetics, growing chronic kidney disease prevalence, an aging population, declining calcium levels, and expanded clinical trials. North America, with its large elderly population and research, plays an important role. OPKO HEALTH, INC., Amgen Inc., Sanofi SA are among the key companies.

However, significant treatment prices, such as Sensipar's $859 for 30 tablets, pose complications. The dominance of the Vitamin D Analogs segment is expected to be driven by efficacy and the prevalence of chronic kidney disease in North America. COVID-19 has an effect on parathyroid function, both directly and indirectly through vitamin D deficiency and secondary hyperparathyroidism.

Why Purchase the Report?

• To visualize the global secondary hyperparathyroidism treatment market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of secondary hyperparathyroidism treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global secondary hyperparathyroidism treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies